Akero Therapeutics

We are growing! As we continue to progress our commitment to advancing therapies in serious metabolic diseases, we are hiring for the following positions: – Director / Sr. Director - Clinical Development – Principal Clinical Scientist - Clinical Development – Sr. Program Director - Regulatory and Clinical Development If you’re passionate about bringing meaningful therapies to patients living with metabolic disease and want to play a key role in late-stage development strategy and execution, we’d love to connect. https://lnkd.in/e_SJqBsv

It was great to connect with our Novo Nordisk colleagues at Liver Forum 20, organized by The Forum for Collaborative Research. Experts across industry, academia, and regulatory agencies came together to discuss the latest advances, challenges, and opportunities in MASH drug development. Continued progress for patients with MASH is fueled by collaboration—diverse perspectives coming together to drive innovation and bring the field closer to improving outcomes for patients. Learn more about the meeting: https://lnkd.in/euFV5fyF #MASH #Liver #Fibrosis #Cirrhosis #DrugDevelopment

In honor of International Women’s Day, we’d like to recognize the women at Akero whose insights, expertise, and leadership strengthen our approach to tackling complex metabolic diseases, such as MASH and MASLD. Across research and development, clinical strategy, operations, and leadership, women throughout our organization are advancing our science with rigor and purpose. Their contributions help accelerate innovation, deepen our understanding of metabolic liver disease, and move us closer to delivering meaningful therapies for patients. #InternationalWomensDay #IWD2026 #WomenInSTEM

This #NationalNutritionMonth, we’re embracing this year’s theme: “Discover the Power of Nutrition”. For people living with MASH and MASLD, nutrition can be a powerful tool for supporting liver health and improving overall wellbeing. Addressing these conditions requires a multifaceted approach including scientific innovation, clinical care, and evidence-based lifestyle strategies. As we work to develop new therapies for metabolic liver disease, we also recognize the broader ecosystem of care in which nutrition plays a foundational role. Learn more about liver-healthy lifestyle guidance from the American Liver Foundation: https://lnkd.in/d-YZqvyt

#NationalSelfCheckMonth highlights the value of routine health assessments and informed screening. #MASH and #MASLD are progressive metabolic diseases that may advance without early symptoms. Understanding your individual risk and seeking regular screenings can help guide meaningful conversations with your doctor and support proactive care decisions. Turn awareness into action today by taking the Liver Education Advocates’ MASH risk assessment and discussing the results with your healthcare provider: https://lnkd.in/eH-ReFbw

As we welcome a new year, we’re reminded of the importance of progress, resilience, and our ongoing commitment to advancing research and therapies to transform the lives of people living with serious metabolic diseases. Wishing you a healthy, hopeful, and inspiring start to 2026!

From our team to yours, Happy Holidays! We’re proud of what we accomplished together this year and grateful for the people who make it all possible. Wishing you all a joyous and restful holiday season.

As 2025 comes to a close, we’re grateful for the dedication of our team, partners, investigators, patients, and advocates who have supported #TeamAkero on our journey to deliver new treatments for MASH. This year, we demonstrated statistically significant evidence of cirrhosis reversal due to MASH in our Phase 2b SYMMETRY trial, completed enrollment in the Phase 3 SYNCHRONY Real-World trial, and finalized the acquisition of Akero by Novo Nordisk to join forces in our shared mission. We are energized by the momentum behind our science, our team, and our commitment to patients and look forward to continued progress in 2026.

We’re proud to announce that the acquisition of Akero by Novo Nordisk has been completed. This marks an exciting milestone for the continued advancement of efruxifermin, which offers class-leading potential for the treatment of MASH and compliments Novo Nordisk’s existing metabolic disease portfolio. Read more: https://lnkd.in/enJf2ksh

🦃 Wishing you a healthy and happy #Thanksgiving from all of us at #TeamAkero!